



Biotechnological Solutions for Emerging Zoonotic Diseases in Veterinary Medicine

Dong Zhou*

Department of Applied Sciences, North Umbria University, Newcastle upon Tyne, United Kingdom

Abstract

Emerging zoonotic diseases pose significant threats to animal and human health, necessitating innovative biotechnological solutions in veterinary medicine. Advances in genetic engineering, molecular diagnostics, and vaccine development have revolutionized disease surveillance, prevention, and treatment. Biotechnology enables rapid pathogen detection through PCR-based assays, CRISPR technology, and next-generation sequencing. Novel vaccine strategies, including recombinant and mRNA-based vaccines, offer enhanced immunogenicity and targeted protection. Additionally, biopharmaceuticals and probiotics contribute to antimicrobial resistance mitigation, ensuring sustainable disease management. This review explores cutting-edge biotechnological interventions addressing zoonotic disease challenges, highlighting their implications for global One Health initiatives and veterinary public health.

Keywords: Zoonotic diseases; Biotechnology; Veterinary medicine; Genetic engineering; Molecular diagnostics; Vaccine development

Introduction

Zoonotic diseases, which are transmitted between animals and humans, continue to pose significant public health and economic challenges worldwide [1]. These diseases, caused by bacteria, viruses, parasites, or fungi, account for a substantial proportion of emerging infectious threats, including outbreaks of avian influenza, rabies, and coronaviruses. The increasing frequency of zoonotic disease emergence is driven by factors such as habitat destruction, climate change, globalization, and intensified livestock production. Addressing these threats requires a multidisciplinary approach that integrates veterinary science, biotechnology, and public health under the One Health framework [2].

Biotechnology has revolutionized veterinary medicine by providing advanced tools for disease detection, prevention, and treatment. Innovations in genetic engineering, molecular diagnostics, and vaccine development have improved the ability to monitor and control zoonotic pathogens efficiently. Techniques such as polymerase chain reaction (PCR), CRISPR-based gene editing, and next-generation sequencing enable early and precise pathogen identification, enhancing outbreak preparedness. Additionally, biopharmaceuticals and probiotics offer novel approaches to managing antimicrobial resistance, a growing concern in veterinary and human medicine [3].

This review explores the role of biotechnological advancements in combating emerging zoonotic diseases in veterinary medicine. It highlights the latest developments in diagnostics, vaccines, and therapeutic strategies while discussing their implications for disease control, animal health, and global public health security. By leveraging biotechnology, veterinary medicine can play a crucial role in mitigating zoonotic threats and supporting sustainable disease management practices [4].

Discussion

Biotechnological advancements have significantly transformed the management of emerging zoonotic diseases in veterinary medicine, offering innovative solutions for early detection, prevention, and treatment. The integration of molecular diagnostics, genetic

engineering, and novel therapeutic approaches has enhanced the ability to monitor and control zoonotic pathogens, reducing their impact on both animal and human populations [5].

Molecular Diagnostics and Early Disease Detection

Early and accurate detection of zoonotic pathogens is crucial for effective disease control. Polymerase chain reaction (PCR), next-generation sequencing (NGS), and CRISPR-based detection systems have revolutionized veterinary diagnostics. These technologies enable rapid identification of pathogens at the molecular level, even before clinical symptoms appear. Metagenomic sequencing has further improved pathogen surveillance by detecting emerging and unknown infectious agents, facilitating timely intervention strategies [6].

Vaccine Development and Immunization Strategies

Advances in vaccine biotechnology have led to the development of recombinant, DNA, and mRNA vaccines, which offer improved safety and efficacy compared to traditional vaccines. For instance, recombinant vector vaccines have been successfully used in controlling rabies and avian influenza in animals. mRNA vaccine platforms, initially developed for human use, are now being adapted for veterinary applications, ensuring rapid response to emerging zoonotic threats. Additionally, nanoparticle-based vaccine delivery systems enhance antigen stability and immune response, contributing to long-term disease prevention [7].

Genetic Engineering for Disease Resistance

*Corresponding author: Dong Zhou, Department of Applied Sciences, North Umbria University, Newcastle upon Tyne, United Kingdom, E-mail: dongzhou@gmail.com

Received: 02-Jan-2025, Manuscript No: jflp-25-162417, Editor assigned: 04-Jan-2025, PreQC No: jflp-25-162417 (PQ), Reviewed: 18-Jan-2025, QCNo: jflp-25-162417, Revised: 23-Jan-2025, Manuscript No: jflp-25-162417 (R), Published: 30-Jan-2025, DOI: 10.4172/2332-2608.1000612

Citation: Dong Z (2025) Biotechnological Solutions for Emerging Zoonotic Diseases in Veterinary Medicine. J Fisheries Livest Prod 13: 612.

Copyright: © 2025 Dong Z. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CRISPR-Cas gene-editing technology has opened new possibilities in enhancing disease resistance in livestock. By modifying specific genes associated with susceptibility to infections, scientists have developed disease-resistant breeds, reducing the need for antibiotics and minimizing zoonotic transmission risks. For example, gene-edited pigs resistant to porcine reproductive and respiratory syndrome (PRRS) demonstrate the potential of genetic engineering in veterinary disease management [8].

Antimicrobial Resistance and Alternative Therapeutics

The overuse of antibiotics in veterinary medicine has contributed to the rise of antimicrobial resistance (AMR), posing a severe threat to both animal and human health. Biotechnology offers alternative solutions, including bacteriophage therapy, antimicrobial peptides, and probiotics, which can replace or complement traditional antibiotics. Biopharmaceuticals, such as monoclonal antibodies, are also emerging as targeted therapies for bacterial and viral infections, reducing the reliance on conventional antimicrobials [9].

One Health Implications and Future Perspectives

The One Health approach emphasizes the interconnectedness of human, animal, and environmental health, highlighting the need for collaborative efforts in managing zoonotic diseases. Biotechnological interventions in veterinary medicine not only protect animal health but also prevent spillover events that can lead to human pandemics. Future research should focus on enhancing biosafety measures, developing cost-effective diagnostic tools, and expanding the use of artificial intelligence in disease surveillance. Additionally, policy frameworks should support the responsible implementation of biotechnological innovations to ensure ethical and sustainable disease management practices [10].

Conclusion

Biotechnology continues to play a pivotal role in addressing emerging zoonotic diseases in veterinary medicine. By integrating

advanced diagnostic tools, vaccine innovations, genetic engineering, and alternative therapeutics, veterinary professionals can improve disease control strategies and reduce zoonotic transmission risks. As global health challenges evolve, the adoption of biotechnology-driven solutions will be essential in safeguarding both animal and human populations from future infectious disease threats.

References

1. CSA (2022) Agricultural Sample Survey, Volume II report on livestock and livestock characteristics (private peasant holdings). Central Statistical Agency (CSA): Addis Ababa, Ethiopia.
2. FAO (2010) Chicken genetic resources used in smallholder production systems and opportunities for their development. FAO Smallholder Poultry Production Paper NO. 5.
3. Solomon D (2007) Suitability of hay box brooding technology to the rural household poultry production system. Inter J Res Sust Develop World Agri CIPAV, Cali, Colombia.
4. Biazen A, Mengistu U, Negassi A, Getenet A, Solomon A, et al. (2019b) FAO Poultry Sector Ethiopia, Animal Production and Health Livestock Country Reviews. No. 11. Rome.
5. Shapiro BI, Gebru G, Desta S, Negassa A, Nigussie K, et al. (2015) Ethiopia livestock master plan. ILRI Project Report. Inter Live Res Inst (ILRI).
6. CSA (2020) Agricultural Sample Survey Volume II report on livestock and livestock characteristics (private peasant holdings). Central Statistical Agency (CSA): Addis Ababa, Ethiopia.
7. Kumsa B, Beyecha K, Geloye M (2008) Ectoparasites of sheep in three agro-ecological zones in central Oromia, Ethiopia. Onderstepoort J Vet Res 79: 1-7.
8. Fitsum M, Aliy M (2014) Poultry Production System and Role of Poultry Production in Tigray Region, Northern Ethiopia: A Review. J Biol Agri Healthc 4: 27.
9. Solomon D (2007) Suitability of hay box brooding technology to the rural household poultry production system. Inter J Res Sust Develop World Agri CIPAV, Cali, Colombia.
10. CSA (2022) Agricultural Sample Survey, Volume II report on livestock and livestock characteristics (private peasant holdings). Central Statistical Agency (CSA): Addis Ababa, Ethiopia.